Literature DB >> 719984

The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration.

A J Wood, D M Kornhauser, G R Wilkinson, D G Shand, R A Branch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 719984     DOI： 10.2165/00003088-197803060-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  16 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function.

Authors:  J CAESAR; S SHALDON; L CHIANDUSSI; L GUEVARA; S SHERLOCK
Journal:  Clin Sci       Date:  1961-08       Impact factor: 6.124

3.  Effect of portacaval shunt on the disposition of drugs with and without first-pass effect.

Authors:  R Gugler; P Lain; D L Azarnoff
Journal:  J Pharmacol Exp Ther       Date:  1975-12       Impact factor: 4.030

4.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

5.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

6.  Plasma propranolol levels in adults with observations in four children.

Authors:  D G Shand; E M Nuckolls; J A Oates
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.875

7.  Metabolism of niridazole in various species, including man.

Authors:  J W Faigle; H Keberle
Journal:  Ann N Y Acad Sci       Date:  1969-10-06       Impact factor: 5.691

Review 8.  Effects of liver disease on drug disposition in man.

Authors:  G R Wilkinson; S Schenker
Journal:  Biochem Pharmacol       Date:  1976-12-15       Impact factor: 5.858

9.  Biological determinants of propranolol disposition in man.

Authors:  D M Kornhauser; A J Wood; R E Vestal; G R Wilkinson; R A Branch; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1978-02       Impact factor: 6.875

10.  Mechanism for reduced drug clearance in patients with cirrhosis.

Authors:  D Pessayre; D Lebrec; V Descatoire; M Peignoux; J P Benhamou
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682
View more
  32 in total

Review 1.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 3.  Guide to drug dosage in hepatic disease.

Authors:  N M Bass; R L Williams
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

4.  Time-dependent modifications of splanchnic circulation in female pigs submitted to end-to-side portacaval anastomosis.

Authors:  G Molino; P Avagnina; C Garrone; G Sansoè; M M Degerfeld; P Peretti; M Tinivella; S Bianco
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

5.  A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

Authors:  R G Watson; W Bastain; K A Larkin; J R Hayes; J A McAinsh; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 6.  Drug kinetics and hepatic blood flow.

Authors:  C F George
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

Review 7.  Hepatic first-pass metabolism in liver disease.

Authors:  T F Blaschke; P C Rubin
Journal:  Clin Pharmacokinet       Date:  1979 Nov-Dec       Impact factor: 6.447

8.  Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.

Authors:  A Somogyi; M Albrecht; G Kliems; K Schäfer; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

9.  Roles of hepatic blood flow and enzyme activity in the kinetics of propranolol and sotalol.

Authors:  H I Pirttiaho; E A Sotaniemi; R O Pelkonen; U Pitkänen; M Anttila; H Sundqvist
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

10.  Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.

Authors:  Desmond Padhi; Robert Z Harris; Margaret Salfi; Robert J Noveck; John T Sullivan
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.